Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 482-330-9 | CAS number: 144020-22-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Repeated dose toxicity: oral
Administrative data
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 007
- Report date:
- 2007
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.7 (Repeated Dose (28 Days) Toxicity (Oral))
- Version / remarks:
- and OECD 407 and METI
- Deviations:
- no
- Remarks:
- No deviations from protocol
- GLP compliance:
- yes
Test material
- Reference substance name:
- -
- EC Number:
- 482-330-9
- EC Name:
- -
- Cas Number:
- 144020-22-4
- Molecular formula:
- C17H26O
- IUPAC Name:
- 1-[(1E,5Z,9Z)-2,5,10-trimethylcyclododeca-1,5,9-trien-1-yl]ethan-1-one; 1-[(1R)-2,5,10-trimethylcyclododeca-2,5,9-trien-1-yl]ethan-1-one; 1-[(1R)-4,9-dimethyl-12-methylidenecyclododeca-4,8-dien-1-yl]ethan-1-one; 1-[(1S)-2,5,10-trimethylcyclododeca-2,5,9-trien-1-yl]ethan-1-one; 1-[(1S)-4,9-dimethyl-12-methylidenecyclododeca-4,8-dien-1-yl]ethan-1-one
Constituent 1
Test animals
- Species:
- rat
- Strain:
- other: Crl:CD (SD) rats (Charles River (UK))
- Sex:
- male/female
Administration / exposure
- Route of administration:
- oral: unspecified
- Vehicle:
- corn oil
- Details on oral exposure:
- Method of administration:
Gavage - Duration of treatment / exposure:
- Test duration: 28 days
- Frequency of treatment:
- Dosing regime: 7 days/week
- No. of animals per sex per dose:
- Male: 10 animals at 0 mg/kg bw/day
Male: 5 animals at 15 mg/kg bw/day
Male: 5 animals at 150 mg/kg bw/day
Male: 10 animals at 1000 mg/kg bw/day
Female: 10 animals at 0 mg/kg bw/day
Female: 5 animals at 15 mg/kg bw/day
Female: 5 animals at 150 mg/kg bw/day
Female: 10 animals at 1000 mg/kg bw/day
Results and discussion
Results of examinations
- Details on results:
- Clinical observations:
There were no unscheduled deaths, no clinical signs or
effects on sensory reactivity grip strength or motor
activity considered indicative of an effect of treatment.
The general appearance and behaviour of the animals were
unaffected by treatment.
Laboratory findings:
All animals receiving 1000 mg/kg/day showed post-dose
salivation. The salivation was present either immediately
after dosing or at the check performed after completion of
dosing the group and it had generally resolved by the last
check of the day (approx 3-4 hours post-dose).
No post dose signs were observed in animals receiving 15
mg/kg/day.
Effects in organs:
Treatment-related findings were seen in the liver and
thyroids of both sexes given 1000 mg/kg/day and in the
spleen of females of this dose group. They comprised
centrilobular or generalised hepatocyte hypertrophy in the
liver, follicular cell hypertrophy in the thyroids, and an
increased severity of haemosiderosis and increased incidence
of extramedullary haemopoiesis in the spleen. Centrilobular
or generalised hepatocyte hypertrophy was also seen in
several females given 150 mg/kg/day. Following a 2-week
recovery period, there was evidence of partial or complete
recovery from all changes.
Effect levels
open allclose all
- Dose descriptor:
- NOAEL
- Effect level:
- 150 mg/kg bw/day (nominal)
- Basis for effect level:
- other: original NCD unit is mg/kg/day.
- Dose descriptor:
- NOEL
- Effect level:
- 150 mg/kg bw/day (nominal)
- Basis for effect level:
- other: original NCD unit is mg/kg/day.
Target system / organ toxicity
- Critical effects observed:
- not specified
Any other information on results incl. tables
There were no unscheduled deaths, no clinical signs or effects on sensory reactivity grip strength or motor activity considered indicative of an effect of treatment. There were no toxicologically important bodyweight changes and food consumption was unaffected by treatment. Treatment resulted in lower group mean haematocrit and haemoglobin for females at 1000 mg/kg/day, increased group mean platelet counts for both sexes and activated partial thromboplastin times for males at 1000 mg/kg/day. At the end of the recovery period, general recovery from the previous changes in red blood cell parameters was evident, however higher than control platelet counts were still evident in females previously treated at 1000 mg/kg/day, though magnitude of difference was much less than during treatment. Higher group mean bilirubin and cholesterol and lower ALP, AST, glucose for both sexes and lower ALT in males, were recorded for animals receiving 1000 mg/kg/day. Males receiving 150 mg/kg/day also recorded lower AST and glucose compared with controls. In addition, higher than control group mean total protein, albumin, calcium and phosphorus and lower mean chloride and AG ratios were recorded for both sexes receiving 1000 mg/kg/day. No toxicologically important changes were recorded at the end of the recovery period, indicating general recovery from the previous effects of treatment. Lower group mean urinary protein was recorded for both sexes (dose related in females) receiving 1000 mg/kg/day and in females receiving 150 or 15 mg/g/day when compared with control. At the end of the recovery period, these values were considered similar to controls.
Higher than control adjusted group mean liver weights were recorded for both sexes at 1000 mg/kg/day and for females at 150 mg/kg/day. Group mean adjusted kidney weights were higher for females receiving 150 or 1000 mg/kg/day. At the end of the recovery period, higher than control group mean adjust liver and kidney weights were still evident in females previously treated at 1000 mg/kg/day though recovery was evident. Enlargement of the liver was seen in one male rat and all female rats treated at 1000 mg/kg/day. Treatment-related histopathological findings were seen in the liver and thyroids of both sexes given 1000 mg/kg/day and in the spleen of females of this dose group. They comprised centrilobular or generalised hepatocyte hypertrophy in the liver, follicular cell hypertrophy in the thyroids, and an increased severity of haemosiderosis and increased incidence of extramedullary haemopoiesis in the spleen. Centrilobular or generalised hepatocyte hypertrophy was also seen in several females given 150 mg/kg/day. Following a 2-week recovery period, there was evidence of partial or complete recovery from these changes.
Applicant's summary and conclusion
- Conclusions:
- Administration of Trimofix O by oral gavage to rats for 4 weeks followed by a 2 week recovery period at doses of 1000 mg/kg/day were associated with a number of differences from controls, which taken as a whole were considered to represent minor but generally reversible toxicity.
Treatment-related findings were also evident at 150 mg/kg/day, but the degree of difference and number of changes seen at this level was less than at 1000 mg/kg/day. Thus as good evidence of recovery was seen at 1000 mg/kg/day, 150 mg/kg/day was classed as the highest NOAEL on this study. - Executive summary:
Administration of Trimofix O by oral gavage to rats for 4 weeks followed by a 2 week recovery period at doses of 1000 mg/kg/day were associated with a number of differences from controls, which taken as a whole were considered to represent minor but generally reversible toxicity. Treatment-related findings were also evident at 150 mg/kg/day, but the degree of difference and number of changes seen at this level was less than at 1000 mg/kg/day. Thus as good evidence of recovery was seen at 1000 mg/kg/day, 150 mg/kg/day was classed as the highest NOAEL on this study.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

EU Privacy Disclaimer
This website uses cookies to ensure you get the best experience on our websites.